In the pooled analysis from LUX-Lung 3 and 6, presented this year at ASCO, afatinib prolonged survival of lung cancer patients whose tumors have common EGFR mutations by a median of three months compared with standard chemotherapy and significantly reduced the risk of death by 19%. Here, EGFR is linked to lung cancer.